Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuate
暂无分享,去创建一个
W. Gregory | R. Longo | J. O’Dwyer | A. Rawstron | T. Munir | A. Varghese | P. Hillmen | A. Smith | L. McParland | D. Howard | Alexandra Smith | A. Chalmers